Eventide Asset Management’s Aktis Oncology AKTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.7M Buy
1,065,000
+558,000
+110% +$13.6M 0.29% 111
2026
Q2
$16.3M Hold
507,000
– – 0.22% 123
2026
Q1
$9.07M Buy
+507,000
New +$9.8M 0.15% 145

Other funds holding AKTS

Eventide Asset Management's AKTS Position: Q3 2026 in Review

Eventide Asset Management increased its Aktis Oncology (AKTS) stake by 110% in Q3 2026, buying an estimated $13.6M and bringing the position to 1,065,000 shares worth $20.7M. The position accounts for 0.29% of the portfolio, ranked #111.

Eventide Asset Management first reported a position in AKTS in Q1 2026 and has held it in 3 quarters since. 123 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.

  • Eventide Asset Management held 1,065,000 shares of Aktis Oncology worth $20.7M as of Q3 2026.
  • Eventide Asset Management bought 558,000 Aktis Oncology shares in Q3 2026, an estimated $13.6M.
  • Aktis Oncology made up 0.29% of Eventide Asset Management's portfolio in Q3 2026, its #111 holding.
  • Eventide Asset Management first reported a position in Aktis Oncology in Q1 2026 and has held it in 3 quarters since.
  • 123 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.